Mylan gets worldwide rights to glatiramer acetate depot

Mapi-Pharma Ltd. (Ness Ziona, Israel) granted Mylan N.V. (NASDAQ:MYL) exclusive, worldwide rights to develop and commercialize glatiramer acetate depot (GA Depot). The long-acting depot formulation of glatiramer acetate, a selective major histocompatibility complex class II (MHCII) modulator, has completed a Phase II trial to treat relapsing-remitting multiple sclerosis (RRMS). Mylan plans to submit an NDA for the product in late 2020 or early 2021...